|
ARIZONA
NEVADA
NEW MEXICO
UTAH
Logan
 The
Spendlove Research Foundation was founded in 1989 and is funded through
an endowment established by Dr. Rex S. and Reta Spendlove. Dr. Spendlove
is the Founder of Hyclone Laboratories, a leading producer and distributor
of cell culture media products throughout the world. From its inception
up until 1997 the Spendlove Research Foundation supported outside researchers
through capital investments and other forms of financial support. In March
of 1997 the Spendlove Research Foundation changed its strategy to concentrating
on and supporting its own research projects. This has allowed the Spendlove
Research Foundation to control both the direction and the emphasis of
various research and development projects. The Spendlove Research Foundation
is located in beautiful Cache Valley in Northern Utah near Utah State
University in Logan. The close proximity to the University allows the
Foundation to hire highly trained and qualified individuals who desire
to continue their education in the pursuit of advanced degrees. Our long-term
research goals focus in the area of in vivo cell culture simulation. This
research centers on specialty cell culture media that will eventually
allow researchers to control the activities of the cell through the media
and cell environment. In order to achieve that end, we are developing
special analytical systems to allow us to measure the biochemical components
in blood, organs, and cells. We are in the business of technology development
and transfer. We develop unique and beneficial technologies in-house and
out-license them for commercialization. In order to increase the probability
of commercialization success, we will generally give narrow rather than
broad licenses - licensing the technology to many companies, to sell to
many markets.
Salt
Lake City
 Myriad
Genetics Inc. is a biopharmaceutical company focused on the development
of therapeutic and diagnostic products using genomic and proteomic technologies.
The Company's emphasis on product development is demonstrated in its major
business components: Therapeutic product development in important disease
areas. Identification of disease-causing genes, as potential drug targets,
for major pharmaceutical company partners. Disease pathway discovery through
ProNet® and ProSpec® proteomic technologies to isolate drug targets
for development. Molecular diagnostic testing for inherited risk of disease.
Use of high-throughput DNA sequencing to reveal the genomes of important
animal, plant and microbial species Myriad has two wholly owned subsidiaries
Myriad Pharmaceuticals, Inc., which develops and markets therapeutic compounds,
and Myriad Genetic Laboratories, Inc., which develops and markets proprietary
molecular diagnostic services and has introduced products in the fields
of predictive medicine and personalized medicine. The Company has established
strategic alliances with Bayer, Eli Lilly, Hitachi, Pharmacia, Novartis,
Roche, Schering AG and Schering-Plough.
|
